Denis Smith

11.0k total citations · 2 hit papers
116 papers, 4.1k citations indexed

About

Denis Smith is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Denis Smith has authored 116 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 28 papers in Epidemiology. Recurrent topics in Denis Smith's work include Colorectal Cancer Treatments and Studies (58 papers), Gastric Cancer Management and Outcomes (28 papers) and Neuroendocrine Tumor Research Advances (26 papers). Denis Smith is often cited by papers focused on Colorectal Cancer Treatments and Studies (58 papers), Gastric Cancer Management and Outcomes (28 papers) and Neuroendocrine Tumor Research Advances (26 papers). Denis Smith collaborates with scholars based in France, United Kingdom and United States. Denis Smith's co-authors include Catherine Lombard‐Bohas, Eric Van Cutsem, Laëtitia Dahan, Philippe Ruszniewski, Juan W. Valle, Ivan Borbath, Jean‐Luc Raoul, Éric Raymond, Richard C. Chao and Peter Metrakos and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Denis Smith

109 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

2011 1.8k citations Éric Raymond, Laëtitia Dahan et al. profile →
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

2022 501 citations Luis A. Díaz, Kai‐Keen Shiu et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Denis Smith

Since Specialization

Citations

This map shows the geographic impact of Denis Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis Smith more than expected).

Fields of papers citing papers by Denis Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denis Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis Smith. The network helps show where Denis Smith may publish in the future.

Co-authorship network of co-authors of Denis Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Denis Smith. A scholar is included among the top collaborators of Denis Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denis Smith. Denis Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES) 2025 ·Digestive and Liver Disease ·Jérémie H. Lefèvre, Olivier Dubreuil, Raphaël Colle, David Tougeron, Angélique Vienot, Aurélien Dupré, (unknown), Denis Smith, (unknown), Benoist Chibaudel, (unknown), Dewi Vernerey, (unknown)	0
2	New RPS20 gene variant in colorectal cancer diagnosis: insight from a large series of patients 2025 ·Familial Cancer ·(unknown), (unknown), A. Fontaine, Denis Smith, (unknown), (unknown), Jacques Mauillon, (unknown), Stéphanie Baert‐Desurmont, Julie Tinat, Claude Houdayer	1
3	532P G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study 2024 ·Annals of Oncology ·Jean‐Baptiste Bachet, (unknown), (unknown), (unknown), Déwi Vernerey, Christophe Boisson, (unknown), (unknown), (unknown), (unknown), Denis Smith, Jérôme Desrame, (unknown), Benoist Chibaudel, (unknown), Patrick Texereau, (unknown), David Tougeron, Christophe Borg	1
4	651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study 2023 ·Annals of Oncology ·Christophe Borg, V. Vendrely, (unknown), Thierry André, (unknown), (unknown), Simon Pernot, O. Bouché, Jérôme Desrame, Christelle de la Fouchardière, Denis Smith, François Ghiringhelli, Angélique Vienot, Éric François, Julien Taı̈eb, Karine Le Malicot, Déwi Vernerey, Aurélia Meurisse, Stéfano Kim	1
5	LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study 2023 ·Annals of Oncology ·(unknown), Thierry André, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, C.J.A. Punt, Denis Smith, Rocio García‐Carbonero, Julia Alcaide, Peter Gibbs, Christelle de la Fouchardière, Fernando Rivera, (unknown), Dung T. Le, Takayuki Yoshino, Yu Zuo, (unknown), David E. Adelberg, Luis A. Díaz	12
6	Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49 2022 ·Digestive and Liver Disease ·Simon Pernot, Olivier Pellerin, Laurent Mineur, (unknown), Denis Smith, Bruno Lapuyade, Claire Gallois, F. Khemissa Akouz, Thierry de Baère, David Tougeron, Anne Thirot‐Bidault, Franck Audemar, (unknown), Cédric Lecaille, (unknown), Côme Lepage, Michel Ducreux, Julien Taı̈eb	6
7	Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study 2022 ·European Journal of Cancer ·Côme Lepage, (unknown), Astrid Lièvre, (unknown), Laëtitia Dahan, David Tougeron, Christos Toumpanakis, (unknown), Catherine Lombard‐Bohas, Ivan Borbath, Romain Coriat, Thierry Lecomte, Rosine Guimbaud, Caroline Pétorin, Jean-Louis Legoux, Pierre Michel, J.Y. Scoazec, Denis Smith, Thomas Walter	13
8	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study breakdown → 2022 ·The Lancet Oncology ·Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Manuel Benavides, Peter Gibbs, (unknown), Fernando Rivera, Elena Élez, Dung T. Le, Takayuki Yoshino, (unknown), David R. Fogelman, Patricia Marinello, Thierry André	501
9	O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer 2021 ·Annals of Oncology ·Thierry André, Kai‐Keen Shiu, (unknown), Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Julia Alcaide, Peter Gibbs, Christelle de la Fouchardière, F. Rivera Herrero, Elena Élez, Johanna C. Bendell, Dung T. Le, Takayuki Yoshino, (unknown), David R. Fogelman, Patricia Marinello, Luis A. Díaz	1
10	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial 2021 ·The Lancet Oncology ·Thierry André, Mayur M. Amonkar, Josephine M. Norquist, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Isabel Sevilla, Christelle de la Fouchardière, Fernando Rivera, Élena Elez, Luis A. Díaz, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Z.H. Farooqui, Dung T. Le	135
11	Evaluation of Nurses’ and Patients’ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study 2020 ·Advances in Therapy ·Brigitte Delemer, (unknown), Romain Coriat, Denis Smith, F. Schillo, I. Raingeard, Iradj Sobhani, Pierre-Luc Etienne, Bénédicte Decoudier, Ségolène Bisot-Locard, Alexandre Santos, Gérald Raverot, Guillaume Cadiot	1
12	Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study 2020 ·British Journal of Cancer ·Simon Pernot, Olivier Pellerin, Pascal Artru, (unknown), Denis Smith, Jean‐Luc Raoul, Christelle de la Fouchardière, Laëtitia Dahan, Rosine Guimbaud, David Sefrioui, Jean–Louis Jouve, Côme Lepage, David Tougeron, Julien Taı̈eb, (unknown)	19
13	Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study 2020 ·Clinical Colorectal Cancer ·Éric François, Laurent Mineur, G. Deplanque, (unknown), Denis Smith, Sophie Gourgou, (unknown), (unknown), (unknown), (unknown), Stéfano Kim, Florence Rollot	6
14	1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial 2020 ·Annals of Oncology ·Côme Lepage, Jean–Marc Phelip, Astrid Lièvre, Karine Le Malicot, David Tougeron, Laëtitia Dahan, Christos Toumpanakis, F. Di Fiore, C. Lombard Bohas, Ivan Borbath, Romain Coriat, Morgane Caulet, Rosine Guimbaud, Caroline Pétorin, Jean-Louis Legoux, J-Y. Scoazec, Pierre Michel, Guillaume Cadiot, Denis Smith, Thomas Walter	5
15	Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort 2019 ·Clinics and Research in Hepatology and Gastroenterology ·Hampig Raphaël Kourié, Édouard Auclin, António Sá Cunha, Sébastien Gaujoux, Matthieu Bruzzi, Alain Sauvanet, Nelson Lourenço, Isabelle Trouilloud, Samy Louafi, (unknown), Jean Christophe Vaillant, Denis Smith, Yann Touchefeu, Jean‐Baptiste Bachet, Daniel Pietrasz, Julien Taı̈eb	10
16	Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study) 2017 ·Annals of Oncology ·Stéfano Kim, Éric François, (unknown), Emmanuelle Samalin, Farid El Hajbi, Nabil Baba-Hamed, Sarah Dumont, Simon Pernot, D. Peiffert, François Ghiringhelli, Olivier Bouché, Jérôme Desrame, Mustapha Zoubir, Aurélie Parzy, Denis Smith, Christelle de la Fouchardière, Bruno Buecher, V. Vendrely, Franck Bonnetain, Christophe Borg	1
17	Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228). 2013 ·Journal of Clinical Oncology ·Françis Lévi, Valérie Boige, Mohamed Hebbar, Denis Smith, Céline Lepère, C. Focan, Rosine Guimbaud, Carlos Carvalho, Salvatore Tumolo, Pasquale F. Innominato, Y. Ajavon, Stéphanie Truant, Denis Castaing, (unknown), F Kunstlinger, Abdoulaye Karaboué, Mohamed Bouchahda, Philippe Rougier, René Adam, Michel Ducreux, (unknown)	1
18	Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) 2012 ·Pancreas ·Aaron I. Vinik, Eric Van Cutsem, Patricia Niccoli, Jean‐Luc Raoul, Yung‐Jue Bang, Ivan Borbath, Catherine Lombard‐Bohas, Juan W. Valle, Peter Metrakos, Denis Smith, Jen‐Shi Chen, Dieter Hoersch, Daniel Castellano, Hagen F. Kennecke, Joel Picus, Guy van Hazel, Shem Patyna, Dongrui R. Lu, Richard C. Chao, Éric Raymond	4
19	Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer 2005 ·Gastroentérologie Clinique et Biologique ·Y. Bécouarn, Anne Rullier, Philippe Gorry, Denis Smith, B. Richard-Molard, (unknown), Patrick Texereau, (unknown), Jean-Louis Legoux, H Lamouliatte, Thierry Frébourg, Sylviane Olschwang, Brigitte Gilbert, (unknown), V. Picot, François Paraf, Michel Longy	7
20	Exploring the Failure to Learn: Crises and the Barriers to Learning 2000 ·Dominic Elliott, Denis Smith, Martina C. McGuinness	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact